Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...